Alps Advisors Inc. raised its position in GW Pharmaceuticals PLC (NASDAQ:GWPH) by 9.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 24,921 shares of the biopharmaceutical company’s stock after buying an additional 2,081 shares during the quarter. Alps Advisors Inc. owned about 0.10% of GW Pharmaceuticals PLC worth $2,529,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. IHT Wealth Management LLC increased its stake in GW Pharmaceuticals PLC by 18.0% in the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 100 shares during the period. Advisor Group Inc. increased its stake in GW Pharmaceuticals PLC by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares during the period. BNP Paribas Arbitrage SA acquired a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth $163,000. Woodmont Investment Counsel LLC acquired a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth $201,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of GW Pharmaceuticals PLC during the 2nd quarter worth $204,000. 75.55% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Alps Advisors Inc. Purchases 2,081 Shares of GW Pharmaceuticals PLC (GWPH)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/12/alps-advisors-inc-purchases-2081-shares-of-gw-pharmaceuticals-plc-gwph.html.

GW Pharmaceuticals PLC (NASDAQ GWPH) traded up $0.35 during trading hours on Friday, reaching $112.17. 214,900 shares of the company’s stock were exchanged, compared to its average volume of 263,801. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39. GW Pharmaceuticals PLC has a 52 week low of $92.65 and a 52 week high of $136.95.

A number of equities analysts have recently weighed in on GWPH shares. Zacks Investment Research raised shares of GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target on the stock in a research note on Monday, July 17th. Maxim Group set a $135.00 price target on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday, August 7th. Cantor Fitzgerald set a $208.00 price target on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price target (down from $162.00) on shares of GW Pharmaceuticals PLC in a research note on Thursday, August 10th. Finally, BidaskClub cut shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $143.05.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.